News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InSite Vision (ISV) Announces Achievement Of The $1 Million Milestone From The Sale Of Besivance® Royalty


2/4/2014 9:36:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that Besivance 2013 net sales achieved the levels necessary to earn InSite Vision an additional $1 million milestone payment from the Besivance royalty purchasers, SWK Funding LLC, a wholly-owned subsidiary of SWK Holdings Corporation (OTCBB: SWKH), and Bess Royalty, L.P. The $16 million total cash consideration to InSite Vision included a $15 million upfront payment in April, 2013, and a $1 million milestone payment which will be paid this month. Besivance (besifloxacin ophthalmic suspension) 0.6% is marketed globally by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, for the treatment of bacterial conjunctivitis.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES